B
BioSpace
Q3 earnings roll on, FDA pushes rare disease, uniQure’s Huntington’s therapy reaches review
0:00-23:00
The majority of the large pharmas have now reported third quarter earnings—spoiler alert: Eli Lilly made more money than anyone expected. Plus, the FDA dropped another initiative aimed at accelerating rare disease treatments; HHS greenlights the compounding of six unapproved peptides; and uniQure’s embattled gene therapy for Huntington’s disease has finally been accepted for review.
Publisher
BioSpace
Published
November 4, 2026
Duration
23 min
Format
Podcast
Category
Issues · Science
Source
RSS feed
B
BioSpace
@biospace
#q3earningsroll #fdapushesrare #uniqureshuntingtonstherapy #lifesciences
